Anaphylactic reaction after injection of glatiramer acetate (copaxone®) in patients with relapsing-remitting multiple sclerosis

European Neurology

Volumn 66, Issue 6, 2011, Pages 368-370

  Baumgartner, Annette ^a   Stich, Oliver ^a   Rauer, Sebastian ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; BETA1A INTERFERON; CIMETIDINE; CLEMASTINE; DEXAMETHASONE; GLATIRAMER; INTERFERON BETA SERINE; STEROID;

ADULT; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BRONCHOSPASM; CLINICAL ARTICLE; DEPRESSION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ELECTROPHYSIOLOGY; FACE EDEMA; FATIGUE; FEMALE; HEAT SENSATION; HOT FLUSH; HUMAN; HYPOTENSION; INJECTION SITE ERYTHEMA; INJECTION SITE RASH; INTENSIVE CARE; LETTER; MALE; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC INTOLERANCE; PARESTHESIA; PRIORITY JOURNAL; RELAPSING REMITTING MULTIPLE SCLEROSIS; SCALP PRURITUS; SHOCK; SIDE EFFECT; VOMITING;

ADULT; ANAPHYLAXIS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; YOUNG ADULT;

EID: 82055175126     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000334107     Document Type: Letter

References (11)

1. Johnson KP, Brooks BR, Cohen JA, et al: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 2001; 57: 16-24.
2. Perumal J, Filippi M, Ford C, et al: Glatiramer acetate therapy for multiple sclerosis: A review. Expert Opin Drug Metabol Toxicol 2006; 2: 1019-1029. (Pubitemid 44911545)
3. European/Canadian Glatiramer Acetate Study Group; Comi G, Filippi M, Wolinsky JS: European/Canadian multicenter, double- blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49: 290-297. (Pubitemid 32202781)
4. Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP: A prospective, openlabel treatment trial to compare the effect of IFN-α1a (Avonex), IFN-α1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis: Results after 18 months of therapy. Mult Scler 2001; 7: 349-353. (Pubitemid 33138343)
5. Ziemssen T, Neuhaus O, Hohlfeld R: Riskbenefit assessment of glatiramer acetate in multiple sclerosis. Drug Saf 2001; 24: 979-990. (Pubitemid 33097098)
6. Polman CH, Reingold SC, Edan G, et al: Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol 2005; 58: 840-846. (Pubitemid 41746873)
7. Brown SG: Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 2004; 114: 371-376. (Pubitemid 39119039)
8. Rauschka H, Farina C, Sator P, Gudek S, Breier F, Schmidbauer M: Severe anaphylactic reaction to glatiramer acetate with specific IgE. Neurology 2005; 26: 1481-1482. (Pubitemid 40570534)
9. Hegde VL, Venkatesh YP: Anaphylaxis to excipient mannitol: Evidence for an immunoglobulin E-mediated mechanism. Clin Exp Allergy 2004; 34: 1602-1609. (Pubitemid 39389339)
10. McNeill IY: Hypersensitivity reaction to mannitol. Drug Intell Clin Pharm 1985; 19: 552-553. (Pubitemid 15041669)
11. Galetta SL, Markowitz C: US FDA-approved disease-modifying treatments for multiple sclerosis: Review of adverse effect profiles. CNS Drugs 2005; 19: 239-252. (Pubitemid 40460663)